 |
12 Products |  |
71 Diseases | | 12 Products |
|
17 Trials |  |
2045 News |  |
| «12...16171819202122232425262728» |
- Surgery: PEAARS: Pre-Emptive Analgesia in Ano-Rectal Surgery (clinicaltrials.gov) - Mar 31, 2015
P=N/A, N=90, Recruiting, Sponsor: University of Vermont
- | Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Trial completion: Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients (clinicaltrials.gov) - Feb 23, 2015
P4, N=24, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed
- Gralise (gabapentin) / Alvogen
Trial primary completion date: Once Daily Gabapentin in the Treatment of Post Amputation Pain (clinicaltrials.gov) - Feb 5, 2015
P3, N=20, Recruiting, Sponsor: Chicago Anesthesia Pain Specialists
Active, not recruiting --> Completed Trial primary completion date: Feb 2014 --> Feb 2015
- Gralise (gabapentin) / Alvogen
Clinical: Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=44, Not yet recruiting, Sponsor: University of Washington
- Comtan (entacapone) / Novartis, Orion Corp
New P1/2 trial: Effect of Entacapone on Bodyweight Loss in Obese Population (clinicaltrials.gov) - Jan 28, 2015
P1/2, N=30, Recruiting, Sponsor: Kaichun Wu
- |||| Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Trial completion: Effect of VI-0521 (Qsymia (clinicaltrials.gov) - Jan 13, 2015
P4, N=51, Completed, Sponsor: VIVUS, Inc.
Trial primary completion date: Feb 2014 --> Feb 2015 Active, not recruiting --> Completed
- ||||||| Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
Trial completion, Trial primary completion date: BIPARK-I: Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon (clinicaltrials.gov) - Jan 8, 2015
P3, N=600, Completed, Sponsor: Bial - Portela C S.A.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Nov 2013
- ||| Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
Clinical: To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC) (clinicaltrials.gov) - Dec 29, 2014
P=N/A, N=500, Recruiting, Sponsor: Celltrion
- Comtan (entacapone) / Novartis, Orion Corp
Enrollment closed, Trial primary completion date: Treatment of Orthostatic Intolerance (clinicaltrials.gov) - Dec 24, 2014
P1/2, N=150, Active, not recruiting, Sponsor: Satish R. Raj
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Nov 2013 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jan 2018
- Gralise (gabapentin) / Alvogen
Trial primary completion date: A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=120, Recruiting, Sponsor: University of Tennessee
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jan 2018 Trial primary completion date: Mar 2015 --> Mar 2016
- | Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Enrollment closed: Effect of VI-0521 (Qsymia (clinicaltrials.gov) - Oct 2, 2014
P4, N=50, Active, not recruiting, Sponsor: VIVUS, Inc.
Trial primary completion date: Mar 2015 --> Mar 2016 Recruiting --> Active, not recruiting
- | Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
New P4 trial: Effect of VI-0521 (Qsymia (clinicaltrials.gov) - Sep 4, 2014
P4, N=50, Recruiting, Sponsor: VIVUS, Inc.
- Gralise (gabapentin) / Alvogen
Enrollment closed: Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children (clinicaltrials.gov) - Aug 12, 2014
P2, N=40, Active, not recruiting, Sponsor: Scott Schwantes, M.D.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Gralise (gabapentin) / Alvogen
Enrollment change, Trial termination: Efficacy of Gralise (clinicaltrials.gov) - Aug 5, 2014
P4, N=11, Terminated, Sponsor: Rehabilitation Institute of Chicago
Recruiting --> Active, not recruiting N=36 --> 11 | Recruiting --> Terminated; Study ended due to difficulties in recruitment and low enrollment.
- Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Enrollment closed, Trial primary completion date: A Toolbox Approach to Obesity Treatment in Primary Care (clinicaltrials.gov) - Aug 4, 2014
P4, N=350, Active, not recruiting, Sponsor: Denver Health and Hospital Authority
N=36 --> 11 | Recruiting --> Terminated; Study ended due to difficulties in recruitment and low enrollment. Not yet recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jun 2016
- |||||| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
Enrollment open, Head-to-Head: Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease (clinicaltrials.gov) - Jul 27, 2014
P3, N=214, Recruiting, Sponsor: Celltrion
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jun 2016 Not yet recruiting --> Recruiting
- Gralise (gabapentin) / Alvogen
Enrollment change, Trial termination, Trial primary completion date, HEOR: Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer (clinicaltrials.gov) - Jul 16, 2014
P2, N=5, Terminated, Sponsor: University of Wisconsin, Madison
Not yet recruiting --> Recruiting N=60 --> 5 | Recruiting --> Terminated | Trial primary completion date: Jun 2014 --> Jan 2014; Slow accrual
- Gralise (gabapentin) / Alvogen
Trial primary completion date: Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise) (clinicaltrials.gov) - Jul 4, 2014
P=N/A, N=5, Terminated, Sponsor: Massachusetts General Hospital
N=60 --> 5 | Recruiting --> Terminated | Trial primary completion date: Jun 2014 --> Jan 2014; Slow accrual Trial primary completion date: Dec 2014 --> Jun 2014
- Gralise (gabapentin) / Alvogen
Trial termination: Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise) (clinicaltrials.gov) - Jul 4, 2014
P=N/A, N=5, Terminated, Sponsor: Massachusetts General Hospital
Trial primary completion date: Dec 2014 --> Jun 2014 Recruiting --> Terminated; Due to limited population of research participants.
- Gralise (gabapentin) / Alvogen
Enrollment change, Trial termination, Trial primary completion date: Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise) (clinicaltrials.gov) - Jul 4, 2014
P=N/A, N=5, Terminated, Sponsor: Massachusetts General Hospital
Recruiting --> Terminated; Due to limited population of research participants. N=45 --> 5 | Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Jun 2014; Due to limited population of research participants.
- Comtan (entacapone) / Novartis, Orion Corp
Trial initiation date: Pilot Study of Entacapone for Methamphetamine Abuse (clinicaltrials.gov) - Jun 27, 2014
P0, N=32, Recruiting, Sponsor: Oregon Health and Science University
N=45 --> 5 | Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Jun 2014; Due to limited population of research participants. Initiation date: Mar 2014 --> Jun 2014
- Comtan (entacapone) / Novartis, Orion Corp
Enrollment open, Trial initiation date: Pilot Study of Entacapone for Methamphetamine Abuse (clinicaltrials.gov) - Jun 27, 2014
P0, N=32, Recruiting, Sponsor: Oregon Health and Science University
Initiation date: Mar 2014 --> Jun 2014 Not yet recruiting --> Recruiting | Initiation date: Mar 2014 --> Jun 2014
- Gralise (gabapentin) / Alvogen
Trial primary completion date: L12-078: Pain Control With Total Knee Replacement (clinicaltrials.gov) - May 20, 2014
P4, N=72, Enrolling by invitation, Sponsor: Texas Tech University Health Sciences Center
Not yet recruiting --> Recruiting | Initiation date: Mar 2014 --> Jun 2014 Trial primary completion date: Sep 2014 --> Sep 2015
- Gralise (gabapentin) / Alvogen
Trial completion date: L12-078: Pain Control With Total Knee Replacement (clinicaltrials.gov) - May 20, 2014
P4, N=72, Enrolling by invitation, Sponsor: Texas Tech University Health Sciences Center
Trial primary completion date: Sep 2014 --> Sep 2015 Trial completion date: Sep 2014 --> Sep 2015
- |||||||||| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
New P3 trial, Head-to-Head: Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease (clinicaltrials.gov) - Mar 24, 2014
P3, N=214, Not yet recruiting, Sponsor: Celltrion
- levodopa/carbidopa high dose (ND0612H) / Mitsubishi Tanabe
New P1/2 trial: A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients (clinicaltrials.gov) - Mar 24, 2014
P1/2, N=0, Not yet recruiting, Sponsor: NeuroDerm Ltd.
- | Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Enrollment closed: Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients (clinicaltrials.gov) - Mar 24, 2014
P4, N=24, Active, not recruiting, Sponsor: Mayo Clinic
Trial completion date: Sep 2014 --> Sep 2015 Recruiting --> Active, not recruiting
- Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Trial withdrawal: Comparison of the Effect of Intense-Exercise/Moderate-Calorie, Topiramate-Phentermine and Cognitive Behavioral Therapy on Obesity (clinicaltrials.gov) - Jan 13, 2014
P=N/A, N=0, Withdrawn, Sponsor: Department of Veterans Affairs
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Enrollment change: Comparison of the Effect of Intense-Exercise/Moderate-Calorie, Topiramate-Phentermine and Cognitive Behavioral Therapy on Obesity (clinicaltrials.gov) - Jan 13, 2014
P=N/A, N=0, Withdrawn, Sponsor: Department of Veterans Affairs
Not yet recruiting --> Withdrawn N=60 --> 0
- ||||| Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
Enrollment closed: BIPARK-I: Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon (clinicaltrials.gov) - Dec 18, 2013
P3, N=550, Active, not recruiting, Sponsor: Bial - Portela C S.A.
N=60 --> 0 Recruiting --> Active, not recruiting
- | Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
New P4 trial: A Toolbox Approach to Obesity Treatment in Primary Care (clinicaltrials.gov) - Aug 12, 2013
P4, N=350, Not yet recruiting, Sponsor: Denver Health and Hospital Authority
- ||||||| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
Trial completion: An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1 (clinicaltrials.gov) - Jul 29, 2013
P3, N=302, Completed, Sponsor: Celltrion
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
Trial completion: An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1 (clinicaltrials.gov) - Jul 29, 2013
P1, N=174, Completed, Sponsor: Celltrion
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Gralise (gabapentin) / Alvogen
Trial initiation date: Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise) (clinicaltrials.gov) - May 22, 2013
P=N/A, N=45, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Initiation date: Oct 2012 --> May 2013
- Gralise (gabapentin) / Alvogen
Enrollment open: Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise) (clinicaltrials.gov) - May 22, 2013
P=N/A, N=45, Recruiting, Sponsor: Massachusetts General Hospital
Initiation date: Oct 2012 --> May 2013 Not yet recruiting --> Recruiting
- | Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
New P4 trial: Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients (clinicaltrials.gov) - Apr 15, 2013
P4, N=24, Active, not recruiting, Sponsor: Mayo Clinic
- | Nesbell (darbepoetin alfa biosimilar) / Fuji Pharma, Chong Kun Dang, Alvogen, Biocon
Trial completion: Pharmacokinetics Study of CKD-11101 and NESP After SC Administration in Health Male Volunteers (clinicaltrials.gov) - Mar 13, 2013
P1, N=34, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- | Nesbell (darbepoetin alfa biosimilar) / Fuji Pharma, Chong Kun Dang, Alvogen, Biocon
Trial completion: Pharmacokinetics Study of CKD-11101 and NESP After IV Administration in Health Male Volunteers (clinicaltrials.gov) - Mar 13, 2013
P1, N=31, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Not yet recruiting --> Completed Not yet recruiting --> Completed
- Gralise (gabapentin) / Alvogen
Enrollment open: Once Daily Gabapentin in the Treatment of Post Amputation Pain (clinicaltrials.gov) - Mar 11, 2013
P3, N=20, Recruiting, Sponsor: Chicago Anesthesia Pain Specialists
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- Gralise (gabapentin) / Alvogen
New P3 trial: Once Daily Gabapentin in the Treatment of Post Amputation Pain (clinicaltrials.gov) - Jan 24, 2013
P3, N=20, Recruiting, Sponsor: Chicago Anesthesia Pain Specialists
- Gralise (gabapentin) / Alvogen
New P4 trial, Surgery: GRASSP: Gralise (clinicaltrials.gov) - Jan 7, 2013
P4, N=50, Recruiting, Sponsor: University of Rochester
- | Nesbell (darbepoetin alfa biosimilar) / Fuji Pharma, Chong Kun Dang, Alvogen, Biocon
New P1 trial: Pharmacokinetics Study of CKD-11101 and NESP After SC Administration in Health Male Volunteers (clinicaltrials.gov) - Sep 12, 2012
P1, N=34, Completed, Sponsor: Chong Kun Dang Pharmaceutical
- | Nesbell (darbepoetin alfa biosimilar) / Fuji Pharma, Chong Kun Dang, Alvogen, Biocon
New P1 trial: Pharmacokinetics Study of CKD-11101 and NESP After IV Administration in Health Male Volunteers (clinicaltrials.gov) - Sep 11, 2012
P1, N=31, Completed, Sponsor: Chong Kun Dang Pharmaceutical
- | Gralise (gabapentin) / Alvogen
New P4 trial: L12-078: Pain Control With Total Knee Replacement (clinicaltrials.gov) - Sep 5, 2012
P4, N=72, Enrolling by invitation, Sponsor: Texas Tech University Health Sciences Center
- Gralise (gabapentin) / Alvogen
New P4 trial: Efficacy of Gralise (clinicaltrials.gov) - Sep 3, 2012
P4, N=36, Recruiting, Sponsor: Rehabilitation Institute of Chicago
- Gralise (gabapentin) / Alvogen
New P2 trial: Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children (clinicaltrials.gov) - Aug 28, 2012
P2, N=40, Recruiting, Sponsor: Scott Schwantes, M.D.
- Gralise (gabapentin) / Alvogen
Trial initiation date: A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response (clinicaltrials.gov) - Aug 18, 2012
P=N/A, N=120, Recruiting, Sponsor: University of Tennessee
Not yet recruiting --> Recruiting Initiation date: Jan 2012 --> Aug 2012
- Gralise (gabapentin) / Alvogen
Enrollment open: A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response (clinicaltrials.gov) - Aug 18, 2012
P=N/A, N=120, Recruiting, Sponsor: University of Tennessee
Initiation date: Jan 2012 --> Aug 2012 Not yet recruiting --> Recruiting
- ||| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
Trial completion: Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS) (clinicaltrials.gov) - Aug 15, 2012
P1, N=257, Completed, Sponsor: Celltrion
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
Trial completion: Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA) (clinicaltrials.gov) - Aug 15, 2012
P3, N=617, Completed, Sponsor: Celltrion
Active, not recruiting --> Completed Active, not recruiting --> Completed